In April 2009, Sepracor initiated two additional pediatric studies in accordance with the FDA's Written Request. The FDA has notified us that these two studies have been put on clinical hold due to its concerns regarding non-clinical data that could be relevant to the administration of eszopiclone in children. The clinical hold does not relate to any findings observed in the pediatric clinical studies...It is not clear exactly what is being studied. But ClinicalTrials.gov lists these three trials of Lunesta in kids. One for "Children and Adolescents With Attention-Deficit/Hyperactivity Disorder - Associated Insomnia," a second for the long-term safety effects in the same condition, and a third to see whether kids recovering from burns get better sleep with Lunesta or Takeda's Rozerem.
The math suggests one of these trials is still under way. If you really want to scare yourself regarding the amibitions Sepracor has for Lunesta, do a search for the brand name. It brings up 48 different tests for unapproved indications as varied as use in patients with Parkinson's Disease, shift workers, schizophrenia, cancer and low back pain.
Hat tip to Internet Drug News.
- End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight
- Sepracor CEO Got 44% Raise as He Planned 940 Layoffs
- Sanofi, Sepracor Keep Local Politicians in Thrall Over Taxes
- Insomnia and Antidepressant Sales Give Lie to DTC Myths
- Lilly, Barr, AZ and Sepracor Were Generous to Sen. Hatch's Utah Charity
- Sepracor Announces 940 Layoffs; Achieves the Impossible on Lunesta Sales